Current issues and perspectives in PD-1 blockade cancer immunotherapy

Kenji Chamoto, Ryusuke Hatae, Tasuku Honjo

Research output: Contribution to journalReview articlepeer-review

104 Citations (Scopus)


Programmed cell death 1 (PD-1) signal receptor blockade has revolutionized the field of cancer therapy. Despite their considerable potential for treating certain cancers, drugs targeting PD-1 still present two main drawbacks: the substantial number of unresponsive patients and/or patients showing recurrences, and side effects associated with the autoimmune response. These drawbacks highlight the need for further investigation of the mechanisms underlying the therapeutic effects, as well as the need to develop novel biomarkers to predict the lack of treatment response and to monitor potential adverse events. Combination therapy is a promising approach to improve the efficacy of PD-1 blockade therapy. Considering the increasing number of patients with cancer worldwide, solving the above issues is central to the field of cancer immunotherapy. In this review, we discuss these issues and clinical perspectives associated with PD-1 blockade cancer immunotherapy.

Original languageEnglish
Pages (from-to)790-800
Number of pages11
JournalInternational Journal of Clinical Oncology
Issue number5
Publication statusPublished - May 1 2020

All Science Journal Classification (ASJC) codes

  • Surgery
  • Hematology
  • Oncology


Dive into the research topics of 'Current issues and perspectives in PD-1 blockade cancer immunotherapy'. Together they form a unique fingerprint.

Cite this